Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RH324 in Advanced Non-Small Cell Lung Cancer
NCT05580172Phase 1Unknown
- Sponsor
- ReHeva Biosciences
- Start
- Jun 2022
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of RH324 in non-small cell lung cancer (NSCLC) (3 arms), sponsored by ReHeva Biosciences. Primary endpoint: Incidence of Adverse Events Per Common Terminology Criteria for Adverse Events Version 5 at 28 days. Status: unknown.
02
Drugs
RH324
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05580172.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05580172.